NextCure (NASDAQ:NXTC) Trading Down 7.9%

NextCure, Inc. (NASDAQ:NXTC)’s stock price was down 7.9% on Wednesday . The stock traded as low as $1.47 and last traded at $1.51. Approximately 116,132 shares changed hands during trading, a decline of 52% from the average daily volume of 243,919 shares. The stock had previously closed at $1.64.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NXTC shares. Needham & Company LLC reiterated a “buy” rating and set a $4.00 price objective on shares of NextCure in a report on Wednesday, March 20th. HC Wainwright lifted their price objective on NextCure from $5.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 22nd.

NextCure Trading Down 7.9 %

The stock has a market cap of $42.13 million, a P/E ratio of -0.67 and a beta of 0.40. The company has a 50 day simple moving average of $1.72 and a 200 day simple moving average of $1.38.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, March 21st. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.02. As a group, sell-side analysts expect that NextCure, Inc. will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On NextCure

Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of NextCure during the 4th quarter worth approximately $28,000. Jane Street Group LLC acquired a new position in shares of NextCure during the 4th quarter worth approximately $33,000. Cubist Systematic Strategies LLC acquired a new position in shares of NextCure during the 3rd quarter worth approximately $33,000. Tower Research Capital LLC TRC increased its position in shares of NextCure by 100.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 16,375 shares of the company’s stock worth $45,000 after purchasing an additional 8,206 shares during the last quarter. Finally, UBS Group AG increased its position in shares of NextCure by 224.6% during the 1st quarter. UBS Group AG now owns 9,160 shares of the company’s stock worth $45,000 after purchasing an additional 6,338 shares during the last quarter. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.